Biomarker Synergy in Relapsing Multiple Sclerosis: Neurofilament Light Chain and B Cells in Relation to Disease Outcomes
Background and Objectives Anti-CD20 B-cell–depleting therapies demonstrate robust efficacy in people with multiple sclerosis (pwMS). This study addressed the limited understanding of relationships between B-cell populations before and after treatment with ocrelizumab and outcomes in people with relapsing MS (pwRMS) or primary progressive MS (pwPPMS). Methods Total circulating blood B cells and B-cell subsets were examined at baseline and longitudinally in pwRMS and pwPPMS enrolled in the pivotal Phase 3 trials (OPERA I, OPERA II, and ORATORIO). Relationships to disease outcomes before and after treatment with ocrelizumab or comparators were evaluated using generalized linear models and time-to-event analyses. Results Ocrelizumab rapidly depleted total B cells in pwRMS. Blood samples (n = 15,025) were assessed from 3 Phase 3 trials from 2,370 pwMS, demonstrating depletion in all B-cell subsets. Greater depletion was observed with higher ocrelizumab exposure and longer treatment duration. In limited pwMS with detectable B cells, the majority were mature-naive B cells. Findings from the double-blind treatment period considered robust were that pwRMS with detectable mature-naive, memory, or total B cells had greater risk of developing new/enlarging T2 lesions (odds ratio: 3.8–4.9; p < 0.001), while pwPPMS with higher circulating plasmablasts had greater thalamic volume loss (β: −1.4; p < 0.001). Above-median baseline memory B-cell levels identified interferon beta-1a–treated pwRMS at greater risk of disability progression (hazard ratio: 2.0; p < 0.01), with larger numbers of slowly expanding lesions ( p < 0.01). When interferon beta-1a–treated pwRMS presented both high baseline B cells and high serum neurofilament light (NfL; B cells/NfL high), they showed an even higher risk of disability progression (HR: 3.10; p < 0.001). Treatment with ocrelizumab in this subgroup of pwRMS with B cells/NfL high resulted in a near 4-fold reduction in risk of disability progression (HR: 0.25, p < 0.001). Discussion Ocrelizumab treatment depleted total B cells and all B-cell subsets in an exposure-dependent and duration-dependent manner. PwRMS with detectable on-treatment B cells had greater risk of new/enlarging T2 lesions, suggesting that sustained deep B-cell depletion may be important for preventing disability worsening. High baseline B cells when present with high NfL identified a population at increased risk of disease worsening who could benefit from ocrelizumab treatment.
Authors
- Heidemarie Kletzl (ORCID: https://orcid.org/0000-0001-8129-2196)
- Ann E. Herman (ORCID: https://orcid.org/0000-0003-3947-0213)
- Xiaoming Jia (ORCID: https://orcid.org/0000-0002-5104-5431)
- Ludwig Kappos (ORCID: https://orcid.org/0000-0003-4175-5509)
- Koji Shinoda (ORCID: https://orcid.org/0000-0003-3818-9008)
- Harold Koendgen (ORCID: https://orcid.org/0000-0002-8496-4952)
- Christopher T. Harp (ORCID: https://orcid.org/0000-0001-7000-8743)
- Amit Bar‐Or (ORCID: https://orcid.org/0000-0001-7179-0335)
- Anastasiia Raievska
- Ulrike Bonati (ORCID: https://orcid.org/0000-0003-1717-6419)
- Stephen L. Hauser (ORCID: https://orcid.org/0000-0002-4932-4001)
- Nicolas Strauli
Institutions
- F. Hoffmann-La Roche AG (CH)
- University of California, San Francisco (US)
- Genentech (US)
- University Hospital of Basel (CH)
- University of Pennsylvania (US)
Publication Details
- Journal
- Neurology Neuroimmunology & Neuroinflammation
- Published
- 2026-11-12
- DOI
- https://doi.org/10.1212/nxi.0000000000200665
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- GlaxoSmithKline
- Novartis
- Sanofi
- Biogen
- Celgene
- University of Pennsylvania
- F. Hoffmann-La Roche
- Atara Biotherapeutics
- Kiniksa Pharmaceuticals
- Celltrion
- NGM Biopharmaceuticals
- Moderna
- Horizon Therapeutics
- Galápagos
- Shionogi
- Idorsia Pharmaceuticals
- Genentech
- EMD Serono
- Novartis Pharma